Pliant Gross Profit from 2010 to 2024

PLRX Stock

USD 13.53 0.19 1.42%

Pliant Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 1.5 M in 2024. Gross Profit is the profit Pliant Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

1.6 M

Current Value

1.5 M

Quarterly Volatility

23.9 M

Credit Downgrade

Yuan Drop

Covid

Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Net Interest Income of 20.2 M or Interest Income of 21.5 M, as well as many indicators such as Price To Sales Ratio of 707, Dividend Yield of 0.0 or PTB Ratio of 2.36. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.

Check out the analysis of Pliant Therapeutics Correlation against competitors.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Latest Pliant Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Pliant Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Pliant Therapeutics minus its cost of goods sold. It is profit before Pliant Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Pliant Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 9.69 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Pliant Gross Profit Regression Statistics

	Arithmetic Mean	41,932,933
	Geometric Mean	25,968,690
	Coefficient Of Variation	57.08
	Mean Deviation	20,158,756
	Median	57,052,000
	Standard Deviation	23,935,237
	Sample Variance	572.9T
	Range	55.6M
	R-Value	(0.81)
	Mean Square Error	207.7T
	R-Squared	0.66
	Significance	0.0002
	Slope	(4,359,121)
	Total Sum of Squares	8020.5T

Pliant Gross Profit History

	2024	1.5 M
	2023	1.6 M
	2022	6 M
	2021	7.6 M
	2020	41.8 M

Other Fundumenentals of Pliant Therapeutics

Gross Profit Margin

Pliant Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Debt	Deferred Long Term Liab	Net Invested Capital	Capital Stock	Net Working Capital	Capital Surpluse	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.99	0.95	-0.96	0.69	0.53	0.31	1.0	0.89	0.6	0.47	0.79	0.98	-0.9	0.93	0.8	-0.35	0.63	-0.76
Total Stockholder Equity	0.99		0.98	-0.95	0.69	0.46	0.14	0.99	0.9	0.57	0.54	0.73	1.0	-0.93	0.93	0.8	-0.36	0.63	-0.77
Net Tangible Assets	0.95	0.98		-0.91	0.63	0.47	0.07	0.95	0.92	0.6	0.66	0.76	0.99	-0.97	0.93	0.76	-0.22	0.53	-0.65
Retained Earnings	-0.96	-0.95	-0.91		-0.74	-0.31	-0.26	-0.96	-0.9	-0.57	-0.51	-0.69	-0.95	0.84	-0.9	-0.89	0.37	-0.63	0.8
Accounts Payable	0.69	0.69	0.63	-0.74		0.13	0.14	0.69	0.71	0.6	0.25	0.5	0.69	-0.63	0.73	0.66	-0.66	0.29	-0.55
Net Receivables	0.53	0.46	0.47	-0.31	0.13		0.52	0.53	0.36	0.37	-0.08	0.75	0.47	-0.5	0.51	0.14	-0.13	0.19	-0.21
Total Liab	0.31	0.14	0.07	-0.26	0.14	0.52		0.3	0.16	0.35	-0.28	0.52	0.14	-0.08	0.22	0.2	-0.04	0.1	-0.14
Total Current Assets	1.0	0.99	0.95	-0.96	0.69	0.53	0.3		0.89	0.59	0.47	0.78	0.98	-0.9	0.93	0.8	-0.36	0.63	-0.77
Common Stock	0.89	0.9	0.92	-0.9	0.71	0.36	0.16	0.89		0.56	0.68	0.8	0.91	-0.89	0.98	0.92	-0.16	0.27	-0.48
Property Plant Equipment	0.6	0.57	0.6	-0.57	0.6	0.37	0.35	0.59	0.56		0.37	0.72	0.6	-0.73	0.54	0.3	-0.13	0.24	-0.28
Net Debt	0.47	0.54	0.66	-0.51	0.25	-0.08	-0.28	0.47	0.68	0.37		0.36	0.57	-0.69	0.55	0.56	0.43	0.05	-0.08
Deferred Long Term Liab	0.79	0.73	0.76	-0.69	0.5	0.75	0.52	0.78	0.8	0.72	0.36		0.75	-0.81	0.84	0.6	-0.08	0.15	-0.29
Net Invested Capital	0.98	1.0	0.99	-0.95	0.69	0.47	0.14	0.98	0.91	0.6	0.57	0.75		-0.95	0.94	0.79	-0.33	0.6	-0.74
Capital Stock	-0.9	-0.93	-0.97	0.84	-0.63	-0.5	-0.08	-0.9	-0.89	-0.73	-0.69	-0.81	-0.95		-0.9	-0.67	0.14	-0.42	0.52
Net Working Capital	0.93	0.93	0.93	-0.9	0.73	0.51	0.22	0.93	0.98	0.54	0.55	0.84	0.94	-0.9		0.88	-0.29	0.33	-0.55
Capital Surpluse	0.8	0.8	0.76	-0.89	0.66	0.14	0.2	0.8	0.92	0.3	0.56	0.6	0.79	-0.67	0.88		-0.22	0.31	-0.55
Short Term Debt	-0.35	-0.36	-0.22	0.37	-0.66	-0.13	-0.04	-0.36	-0.16	-0.13	0.43	-0.08	-0.33	0.14	-0.29	-0.22		-0.48	0.66
Long Term Debt	0.63	0.63	0.53	-0.63	0.29	0.19	0.1	0.63	0.27	0.24	0.05	0.15	0.6	-0.42	0.33	0.31	-0.48		-0.94
Long Term Debt Total	-0.76	-0.77	-0.65	0.8	-0.55	-0.21	-0.14	-0.77	-0.48	-0.28	-0.08	-0.29	-0.74	0.52	-0.55	-0.55	0.66	-0.94

Click cells to compare fundamentals

About Pliant Therapeutics Financial Statements

Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	1.6 M	1.5 M
Gross Profit Margin	0.56	0.48

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC